AstraZeneca potentially bidding for Serono could make sense.
So says Aurel Leven analyst Jerome Berton.
It would generate synergies, as AstraZeneca is proficient at cutting costs, it wouldn't involve major divestments and would enable the UK company to buy growth from now until the end of the decade until its pipeline starts to deliver again.
It might also be a defense against being swallowed up by Novartis, says Insider.
No comments:
Post a Comment